title: Gene therapy for lung disease: hype or hope?
abstract: Gene therapy, the treatment of any disorder or pathophysiologic state on the basis of the transfer of genetic information, was a high-priority goal in the 1990s. The lung is a major target of gene therapy for genetic disorders, such as cystic fibrosis and alpha1-antitrypsin deficiency, and for other diseases, including lung cancer, malignant mesothelioma, pulmonary inflammation, surfactant deficiency, and pulmonary hypertension. This paper examines general concepts in gene therapy, summarizes the results of published clinical trials, and highlights areas of research aimed at overcoming challenges in the field. Although progress has been slower than anticipated, gene transfer has been safely achieved in patients with lung diseases. Recent advancements in understanding of the molecular basis of lung disease and the development of improved vector systems make it likely that gene therapy will be an important tool for the 21st-century clinician.
authors.affiliation: University of Pennsylvania Medical Center, Philadelphia, USA. albelda@mail.med.upenn.edu
authors.forename: S M
authors.initials: SM
authors.lastname: Albelda
authors.forename: R
authors.initials: R
authors.lastname: Wiewrodt
authors.forename: J B
authors.initials: JB
authors.lastname: Zuckerman
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003550:Cystic Fibrosis / Q000628:therapy; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D008171:Lung Diseases / Q000235:genetics / Q000628:therapy*; D008175:Lung Neoplasms / Q000628:therapy; D016491:Peripheral Vascular Diseases / Q000628:therapy; D019896:alpha 1-Antitrypsin Deficiency / Q000628:therapy